Novo Nordisk’s acquisition of Biocorp demonstrates how insulin manufacturers are looking to take the next step in optimising insulin delivery, opening up better access to AI techniques for MDI users.
Warning: What is discussed in this post is not recommended by the manufacturer and not aligned with the European Medicines Agency sign off for Fiasp. […]
The first of the faster insulins that we saw a great deal of detail about at EASD 2016 is due to arrive at wholesalers near […]
Summary Following issues I experienced with Lantus (Insulin Glargine) in November 2014, I spent some time researching it, looking at absorption and pharmacokinetics and other […]
Copyright © 2024 | WordPress Theme by MH Themes